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Gregory L. Moneta, MD, Section EditorFemoral vs Jugular Venous Catheterization and Risk of Nosocomial
Events in Adults Requiring Acute Renal Replacement Therapy: A
Randomized Controlled Trial
Parienti J-J, ThirionM,Megarbane B, et al; Members of the Cathedia Study
Group. JAMA 2008;299:2413-22.
Conclusions: Jugular venous catheterization vs femoral venous cath-
eterization for initial acute renal replacement therapy may have a higher risk
of hematoma and does not reduce the risk of infectious complications except
perhaps in adults with high body mass index (BMI).
Summary: It is widely believed infectious complications associated
with acute renal replacement therapy are reduced with jugular access vs
femoral access for short-term dialysis. In this study the authors sought to
determine whether jugular catheterization actually decreases the risk of
nosocomial complications compared with femoral catheterization. This was
a randomized, concealed, multicenter, evaluator-blinded, parallel group
trial with 750 patients from three general hospitals in France and nine
tertiary care university medical centers conducted between May 2004
and May 2007. Patients were severely ill and bed-bound with a BMI of
45 and required a first catheter insertion for renal replacement therapy.
The individuals who did the jugular or femoral vein catheterizations were
experienced in both types of replacement sites. The main outcome
measures included rates of infectious complications (catheter coloniza-
tion on removal [primary end point] and catheter related bloodstream
infection).
Patient characteristics and duration of catheterization were similar in
both groups. Hematomas occurred in 13 of 366 patients (3.6%) in the
jugular group compared with four of 370 patients (1.1%) in the femoral
group (P  .03). The risk of catheter colonization at removal of the access
catheter was not significantly different between the jugular and femoral
groups (35.7 vs 40.8 for 1000 catheter-days; hazard ratio [HR], 0.85; 95%
confidence interval [CI], 0.62-1.16; P  .31).
A prespecified subgroup analysis demonstrated significant qualitative
heterogeneity by BMI (P  .001 for the interaction term). There was a
significant increased risk of catheter colonization with jugular catheteriza-
tion vs femoral catheterization (45.4 vs 23.7 per 1000 catheter-days; HR,
2.10; 95% CI, 1.13-3.91; P  .17) and the lowest tercile of BMI (24.2)
Jugular catheterization significantly decreased the incidence of catheter
colonization in the highest tercile of BMI (24.5 vs 50.9 for 1000 catheter-
days; HR, 0.4; 95% CI, 0.23-0.69, P .001). Catheter-related bloodstream
infection was similar in both groups (2.3 vs 1.5 per 1000 catheter-days,
respectively; P  .42).
Comment:The authors’ data are inconsistent with the widely accepted
belief of avoiding femoral catheterization to prevent risk of catheter-related
infection in patients undergoing acute renal replacement therapy, the excep-
tion being those individuals with a significantly increased BMI. However,
this was a large, multicenter randomized trial and the data therefore must be
taken seriously. Except for the patients with elevated BMI, there appears to
be no particular advantage, and perhaps a disadvantage in terms of hema-
toma formation, of using the jugular site vs the femoral site for acute renal
replacement therapy.
Gene Expression Analysis of a Porcine Native Abdominal Aortic An-
eurysm Model
Sadek M, Hynecek RL, Goldenberg S, et al. Surgery 2008;144:252-8.
Conclusion: A porcine model of gene expression during development
of an abdominal aortic aneurysm (AAA) reflects gene expressions found in
human studies and in rodent models of AAA.
Summary: The authors sought to characterize gene expression pat-
terns during development of AAAs in the native pig aorta. Aneurysms were
produced in Yorkshire swine. An infrarenal aortic balloon was dilated and
infused with a solution of type I collagenase/pancreatic porcine elastase.
Control and aneurysmal aortic samples were obtained at 1, 2, and 4 weeks
after aneurysm induction. From these samples RNA was isolated and con-
verted to biotin-modified antisense RNA. This was then hybridized to
porcine genome arrays.
Extracellular matrix remodeling genes that were upregulated in aneu-
rysmal vs control tissue included matrix metalloproteinase-1, -2, -3, and -9,
cathepsin-D, -H, -K, and -S, tissue inhibitor metalloproteinase-1, and
collagen I- 1 chain (P .01). Elastin was temporarily down-regulated (P
.01). Up-regulated inflammatory genes included intercellular adhesion
molecule-2, tumor necrosis factor-. and interleukin (IL) 1 and IL-10,
chemokine receptor-4, and tissue plasminogen activator (P  .01). Athero-
sclerosis and cancer genes were up-regulated. These included apolipoprotein
1352E, acyl-CoA binding protein, friend leukemia virus integration-1, and E26
transformation-specific sequence (P  .01).
Comment: Relevant animal models are obviously important to the
investigation of human disease. There are rodent models for AAA where
gene expressions more or less mimic those of the human condition. Rodent
models, however, are too small to test endovascular devices. The authors of
the current study have demonstrated broad similarities between expressions
that exist in a porcine model of AAA, the human condition, and previously
described rodent models. Although the similarities are not exact, and there
may be differences in temporal expressions of RNA, it is likely this model will
prove useful in investigations of AAA.
Effect of PCI on Quality of Life in Patients with Stable Coronary
Disease
Weintraub WS, Spertus JA, Kolm P, et al; the COURAGE Trial Research
Group. N Engl J Med 2008;359:677-87.
Conclusions: In patients with stable angina, those treated with percu-
taneous coronary intervention (PCI) and optimal medical management, and
those treated with optimal medical management both havemarked improve-
ment in quality of life during follow-up. Initially, those treated with PCI
have a small incremental benefit vs those treated with medical management
alone. After 36 months there is no difference in health status between the
two groups.
Summary: Up to one-third of PCIs have been performed in patients
with stable angina. This is despite the fact that patients with chronic coronary
disease do not have a reduction in major cardiovascular events when treated
with PCI vs best medical management. The argument has been made that
PCI reduces angina symptoms more effectively than best medical manage-
ment and therefore improves quality of life. In this study the authors
analyzed quality of life data to determine whether quality of life was
enhanced by a strategy of PCI in patients with chronic coronary artery
disease.
This was a randomized, not blinded, multicenter trial that took place in
50 centers in the United States and Canada, with sponsorship and oversight
of the trial provided by the Department of Veterans’ Affairs Cooperative
Studies Program. The study randomly assigned 2287 patients with stable
coronary artery disease to optimum medical therapy alone, or PCI plus
optimal medical therapy. Angina-specific health status was assessed using the
Seattle Angina Questionnaire. Scores ranged from 0 to 100, with highest
scores indicating better health status. The RAND 36-Item Health Survey
was used to assess overall physical and mental function.
Upon entering the trial, 22% of the patients were free of angina. After
3 months, 42% in the medical therapy group alone and 53% of the PCI
patients were angina-free (P  .001). The mean  SD Seattle Angina
Questionnaire scores at baseline were 66 25 for physical limitations, 54
32 for angina stability, 69 26 for angina frequency, 87 16 for treatment
satisfaction, and 51 for quality of life. By 3 months these baseline scores
increased more in the PCI group compared with the medical therapy group:
76 24 vs 72 23 for physical limitation (P .004), 77 28 vs 73 27
for anginal stability (P .002), 85 22 vs 80 23 for angina frequency (P
.001), 92 12 vs 90 14 for treatment satisfaction (P .001), and 73
22 vs 68 23 for quality of life (P .001). Overall, incremental benefit for
PCI was present for 6 to 24 months, and patients with more severe angina
had greater benefit from PCI. Similar results occurred in the PCI group in
some, but not all, RAND-36 domains. At 36months there was no significant
difference in health status between the two groups.
Comment: This was not a “head to head” trial of medical therapy vs
PCI. The trial, in fact, compared a strategy of initial PCI plus optimal
medical therapy vs optical medical therapy alone initially. Eventually 21% of
the patients in the medical therapy alone group crossed over and received
PCI. Therefore, what this trial tells us is that in patients with stable coronary
disease, initial management should be optimal medical therapy, and if this is
ineffective, patients should then be treated with coronary intervention.
Endovascular Stenting for Traumatic Aortic Injury: An Emerging New
Standard of Care
Moainie SL, Neschis DG, Gammie JS. Ann Thorac Surg 2008;85:1625-30.
Conclusion: Aortic endografting is a safe and efficient treatment for
traumatic thoracic aorta injury secondary to blunt trauma.
Summary:The authors present a 2-year series of 26 patients with blunt
thoracic aortic injury who were treated with aortic endografts. The authors
retrospectively compare these patients with the prior 26 patients presenting
